Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye

A resurgence of interest and investment in the field of gene therapy, driven in large part by advances in viral vector technology, has recently culminated in United States Food and Drug Administration approval of the first gene therapy product targeting a disease caused by mutations in a single gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, Gerard A., Shalaev, Evgenyi, Karami, Thomas K., Cunningham, James, Slater, Nigel K. H., Rivers, Hongwen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Expert Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308217/
https://www.ncbi.nlm.nih.gov/pubmed/30591984
http://dx.doi.org/10.1007/s11095-018-2554-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308217/
https://www.ncbi.nlm.nih.gov/pubmed/30591984
http://dx.doi.org/10.1007/s11095-018-2554-7

Ejemplares similares